Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: Final results of a phase II study

Anti-Cancer Drugs

Volumn 18, Issue 8, 2007, Pages 963-968

  Eichbaum, Michael H R ^a   Schuetz, Florian ^a   Khbeis, Tanja ^a   Lauschner, Ilka ^a   Foerster, Frank ^b   Sohn, Christof ^a   Schneeweiss, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Outpatient Center for Gynecologic Oncology   (Germany)

Author keywords

Metastatic breast cancer; Salvage therapy; Single agent bendamustine; Weekly administration

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; BENDAMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEMCITABINE; METHOTREXATE; METOCLOPRAMIDE; NAVELBINE; ONDANSETRON; PREDNISOLONE; RANITIDINE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; BRONCHOSPASM; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DYSPNEA; FATIGUE; FEMALE; FLUSHING; HEART PALPITATION; HUMAN; HYPOTENSION; INFECTION; LEUKOPENIA; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PAIN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALVAGE THERAPY; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENES, ERBB-2; HEMATOLOGIC DISEASES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NITROGEN MUSTARD COMPOUNDS; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 34547668529     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328165d11a     Document Type: Article

References (29)

1. Hortobagyi GN. Can we cure limited metastatic breast cancer. J Clin Oncol 2003; 20:620-623.
2. Hryniuk W, Frei III E, Wright FA. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: Summation dose intensity. J Clin Oncol 1998; 16:3137-3147.
3. Jassem J, Pienkowski J, Pluzanska A, Jelic S, Gorbunova V, Mresic-Krmtopic Z, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19:1707-1715.
4. Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 2002; 20:3114-3121.
5. Bonneterre J, Dieras V, Tubiana-Hulin M, Bougnoux P, Bonneterre ME, Delozier T, et al. Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 2004; 9:1466-1471.
6. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21:968-975. Erratum in: J Clin Oncol 2003; 21:2048.
7. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002; 20:2812-2832.
8. O'Shaughnessy J, Nag S, Calderillo-Ruiz G, Jordaan J, Llombert A, Pluzanska A, et al. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Interim results of a global phase III study. Proc Am Soc Clin Oncol 2003; 22:7; (Abstract 25).
9. Albain KS, Nag S, Calderillo-Ruiz G, Jordann JP, Llomber A, Pluzansaka A, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. J Clin Oncol 2004; 22 (Suppl):5s; (Abstract 510).
10. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17:485-493.
11. Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004; 22:3893-3901.
12. Balfour JA, Goa KL. Bendamustine. Drugs 2001; 61:631-638; discussion 639-640.
13. Konstantinov SM, Kostovski A, Topashka-Ancheva M, Genova M, Berger MR. Cytotoxic efficacy of benadmustine in human leukemia and breast cancer cell lines. J Cancer Res Clin Oncol 2002; 129:271-278.
14. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinonoma cell lines. Anticancer Drugs 1996; 7:415-421.
15. Jamitzky T, Lange OF. Third-line chemotherapy with bendamustine for metastatic breast cancer. A prospective pilot study. Eur J Cancer 1996; 32A (Suppl 2): (Abstract PP-7-14).
16. Höffken K, Merkle KH, Schönfelder M, Anger G, Brandtner M, Ridwelski K, Seeber S. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: A phase II-study. J Cancer Res Clin Oncol 1998; 124:627-632.
17. Reichmann U, Huober J, Bokemeyer C, et al. Salvage therapy for metastatic breast cancer: Results of a phase II study with bendamustine. Onkologie 2004; 27 (Suppl 2):38.
18. Schmidt P, Heck HK, Preiss J. Bendamustine/mitoxantrone in the treatment of advanced breast cancer. Eur J Cancer 1999; 35 (Suppl 4):S324; (Abstract 1301).
19. Schöffsky P, Hagedorn V, Grünwald G, Paul H, Merkle K, Kowalski R, Ganser A. Repeated administration of short infusions of bendamustine: A phase I study in patients with advanced progressive solid tumors. J Cancer Res Clin Oncol 2000; 126:41-47.
20. Schöffsky P, Seeland G, Grünwald G et al. Effect of weekly bendamustine on peripheral blood lymphocyte subsets: Results of a phase I study. Proc Am Ass Cancer Res 2000 (Abstract 5299).
21. Schöffsky P, Seeland G, Engel H, Grunwald V, Paul H, Merkle K, et al. Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumors. Ann Oncol 2000; 11:729-734.
22. Gelmon KA, Mackey J, Verma S, Gertler SZ, Bagngemann N, Klimo P, et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 2004; 5:52-58.
23. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38:143-151.
24. Kaplan EL, Meier P. Non-parametric estimation for incomplete observation. J Am Stat Assoc 1958; 47:457-481.
25. Ruffert K. Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil. Zentralbl Chir 1998; 123 (Suppl 5):156-158.
26. von Minckwitz G, Chemozemsky I, Sirakova L, Chilingirov P, Souchon R, Marschner N, et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 2005; 16(8):871-877.
27. Heider A, Köster W, Grote-Kiehn J et al. Bendamustine in untreated small cell lung cancer: Efficacy and toxicity. Eur J Cancer 1999; 35 (Suppl 4):254 (abstract).
28. Reck M, Haering B, Koschel G, Kaukel E, von Pawel J, Gatzemeier U. Chemotherapy of advanced SCLC and NSCLC with bendamustine - a phase II study. Pneumologie 1998; 52:570-573.
29. Schilcher RB, Rahn A, Haase KD. Recurrent ENT tumours treated with bendamustine or gemcitabine and radiotherapy. Proc Am Soc Clin Oncol 2000; 19:426a (Abstract 1682).